Evotec SE — Investor Presentation 2022

Apr 12, 2022

Bringing Probabilities of Success up with the right platforms & technologies Setting the pace …

Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goal", "intend", "look forward to", "may", "plan", "potential", "predict", "project", "should", "will", "would" and similar expressions. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.

Welcome

The Management Team

Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022

Strong overall performance and progress in all "lanes"

Highlights & lowlights 2021

Highlights

• Multiple new & extended integrated drug discovery & development alliances (EVOiR&D)
• Opening of J.POD® Redmond, WA (US); initiation of J.POD® Toulouse, France (EU) (EVOaccess)
• Very good progress in co-owned pipeline (EVOroyalty) (e.g. Bayer/B1 antagonist in DNP, BMS,…)
• Excellent progress in iPSC and protein degradation partnerships with Bristol Myers Squibb (BMS); Opt-in for EVT8683 & start of clinical development
• Multiple new EVT Innovate partnerships in e.g. heart failure, kidney disease, RNA-based drug discovery,…
• Accelerate innovative platforms & technologies EVOcells, EVOpanOmics, EVOpanHunter, E.INVENT.AI, E.SOLVE, E.RNA etc…
• Launch of E.MPD, largest and highest quality molecular patient databases
• Launch of three new BRIDGEs; PRROTECT, an initiative for pandemic preparedness;
• Steady progress within operational venturing strategy (e.g. Exscientia NASDAQ listing)
• NASDAQ listing with total gross proceeds of \$ 500 m

Lowlights

• Bayer discontinued development of eliapixant (BAY1817080) (after period-end)
• Increased costs for capacity expansion; increased costs for energy, …

AP 2025 is fully in swing and accelerated by precision medicine

Action Plan 2025 in numbers

Platforms & technologies are high-tech driven & fully integrated

The drug discovery & development innovation hub – Capabilities & expertise overview

Faster and more learning curves illustrate technology leadership

"Evotec inside" (selected KPI's 2020/21)

62 Patent applications	142 High-throughput screens	12 Pre-clinical development candidates (PDC)	24 INDiGO® programs	> 250 GMP API batches
>10 Precision platforms	>200 bn Data points	>440 bn of iPSC-derived cells	>10,000 compounds assessed as protein degraders	>100 EVOPanHunter projects
>15 Biologics projects	20 Months construction time	>40,000 samples in HT analytics and functional characterisation	>20 consecutive successful manufacturing runs	>90% J.POD® cGMP qualification activities completed
>130 Co-owned pipeline assets	>90 Small molecules	>20 Biologics	>10 Cell & gene therapy	>10 Multiple modalities

Platforms & technologies for more precision and efficiency

Evotec today – 15 Sites & more than 4,200 employees

USA ~500	Austria ~40	Italy ~800	Germany ~1,050	UK ~950	France ~900
 Branford  Princeton  Redmond, WA  Seattle st 1 J.POD®:  Watertown Redmond	 Orth an der Donau	 Verona (Campus Levi-Montalcini)	 Hamburg (HQ) & Goettingen (Manfred Eigen Campus)  Cologne  Munich	 Abingdon (Dorothy Crowfoot Hodgkin Campus)  Alderley Park	 Lyon  Toulouse (Campus Curie) 2st J.POD®: Toulouse

Attracting great talent – Growth enabled by culture & values

Growth of talent in 2021

Boost of expertise in high-impact areas

Recent key hires

• 1) Starting as of 16 May 2022
• 2) Starting as of 1 May 2022

More than a decade of consecutive double digit annual growth

Results versus previous year and guidance

	FY 2020 results	FY 2021 results	Yoy growth reported / like-for-like1)	Guidance March 2021
Group revenues2) (at constant fx-rates)	€ 500.9 m	€ 618.0 m (€ 627.2m)	23% / 27%	570 m € 550 –
R&D3) Unpartnered	€ 46.4 m	€ 58.1 m	25% / 25%	60 m € 50 –
Adjusted Group EBITDA4) (at constant fx-rates)	€ 106.7 m	€ 107.3 m (€115.5 m)	1% / 18%	120 m € 105 –

1) Like-for-like growth is adjusted for Sanofi payment in Q1 2020 and fx-effects 2) Group revenues including revenues from recharges (IFRS 15 material recharges)

3) Average 2020: EUR/US\$ 1.14; EUR/GBP 0.89

4) Unpartnered R&D expenses is excl. expenses for ID-related expenses fully reimbursed by Sanofi under other operating income 5) Adjusted EBITDA before contingent considerations and excluding impairments on goodwill, other intangible & tangible assets as well as the total non-operating result

Significant growth step up and investments towards AP 2025

Guidance 2022

	Guidance 2022	YE 2021	Implied growth at midpoint
Group revenues constant fx-rates1)) (at	720 m € 700 – 690 710 m) (€ –	€ 618.0 m	~15%
R&D2) Unpartnered	80 m € 70 –	€ 58.1 m	~30%
Adjusted EBITDA3) (at constant fx-rates)	120 m € 105 – 110 m) (€ 95 –	€ 107.3 m	At least stable

Approx. € 300 m investment programme for enabling and supporting growth (e.g. capacity expansion, …)

Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022

Main KPIs underline positive development

Condensed income statement 2021 – Evotec SE and subsidiaries

2021	2020	Change
618.0	500.9	23%
24.5%	25.1%	–
(72.2)	(63.9)	13%
(105.4)	(77.2)	37%
(0.7)	(3.2)	nm
67.8	67.2	1%
41.0	48.6	(16)%
107.3	106.6	1%
215.5	6.3	>>>100%

• Revenue growth of 23% (excluding portfolio and fx effects: 27%) driven by all business areas
• Gross margin reflects ramp-up of J.POD® Redmond, WA (US)
• Increase in unpartnered R&D by 25% (€ 58.1 m vs. 2020: € 46.4 m) as planned
• Step-up of SG&A expenses mainly caused by headcounts (+26%), preparation for future growth, starting J.POD® Toulouse (F) and costs for public offering at NASDAQ (> € 3 m, of which € 1.7 m one-off)
• Adj. EBITDA like-for-like growth 18%
• EVOequity: Net income significantly higher due to fair value adjustment of Exscientia Ltd. US IPO

1) Differences may occur due to rounding

2) Adjusted EBITDA excludes changes of contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result.

Revenue growth exceeding guidance – strong fundamentals

Revenues & Gross margin overview

Strong organic growth pointing to healthy demand

Revenue bridge 2020 – 2021 – Evotec SE and subsidiaries

Revenues up in both segments

Segment information 2021 – Evotec SE and subsidiaries

in € m1)

	EVT Execute	EVT Innovate	Inter segment elimination	Evotec Group
Revenues	610.2	147.0	(139.1)	618.0
Gross margin	20.9%	24.9%	–	24.5%
 R&D expenses	(2.9)	(81.9)	12.6.0	(72.2)
 SG&A expenses	(83.9)	(21.5)	–	(105.4)
 Impairment of intangible assets & goodwill	–	(0.7)	–	(0.7)
 Other op. income (expenses), net	22.4	45.4	–	67.8
Operating income	63.1	(22.1)	–	41.0
Adjusted Group EBITDA2)	124.8	(17.5)	–	107.3

• Total revenues show accelerated growth in fourth quarter in both segments
• EVT Execute total revenue growth up 20%; also third party revenue growth was 20%
• EVT Innovate revenues up 39%, due to strong milestone contribution and strong project business
• Adjusted EBITDA with further improvement in Q4 after strong Q3

1) Differences may occur due to rounding

2) Adjusted EBITDA excludes changes of contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result.

Accelerating growth at year end

Condensed income statement Q4 2021 – Evotec SE and subsidiaries

in € m1)
	Q4 2021	Q4 2020	Change
Revenues	187.1	140.5	33%
Gross margin	27.8%	26.0%	–
 R&D expenses	(18.7)	(17.9)	5%
 SG&A expenses	(34.4)	(19.1)	80%
 Impairment of intangible assets & goodwill	–	(3.2)	–
 Other op. income (expenses), net	16.0	16.9	(5)%
Operating income	14.9	13.3	13%
Adjusted Group EBITDA2)	37.2	29.7	25%
Net income	(31.5)	0.4	–

Q4 revenue growth of 33%

• Strong milestone contribution leading to gross margin expansion, despite ramp-up of J.POD® Redmond, WA (US)
• SG&A expenses driven by planned investments to support the operational and financial growth (personnel costs, J.POD® Redmond, WA (US) and costs for public offering and dual listing at NASDAQ)
• EBITDA up 25%
• EVOequity: Net Income influenced by quarterly revaluation of Exscientia Ltd. and decreased share price (non-cash)

2) Adjusted EBITDA excludes changes of contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result.

¹⁾ Differences may occur due to rounding

Exscientia IPO with very strong effect on net income (EVOequity)

Single steps from 2020 to 2021

Strong cash position of > € 850m securing growth ambitions

Single steps from 2020 to 2021

Expanded balance sheet as solid base for future growth

Balance sheet and liquidity – 31 December 2021 vs. 31 Dec. 2020 – Evotec SE & subsidiaries

Balance sheet total in € m	Equity ratio in %	 All relevant balance sheet metrics significantly strengthened due to profitable growth, public US offering and equity portfolio contribution
2,235.2 1,462.9	61.6 49.4	 Total assets, liabilities and equity increased by 53%
		 Equity ratio step up by 12.2%-points
Net Debt ratio (excl. IFRS 16) x adjusted EBITDA1)	Liquidity position in € m	 Leverage ratio remains negative (net cash position) despite high capex for significant growth and EVOequity investments
(5.5) (1.5)	858.2 481.9	 Robust liquidity position following the US listing

Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022

Excellent position for continued growth

Major developments in 2021 (selection)

EVOiR&D

• Multiple new and extended drug discovery and development (e.g. Abivax, EQRx, Bicycle Therapeutics, Evommune, Takeda,…)
• 91% repeat business, extensions, and growth within long-term partnerships

• 800 partners across the industry (~13% up compared to 2020)

• Several new INDiGO agreements signed (e.g., with Oxford Cannabinoid Technologies or third INDiGO programme with Ildong)
• New ADME-collaboration with Amgen
• New collaboration with Novo Nordisk in gene therapy
• EVOaccess: Just Evotec Biologics
  • Several new collaborations (e.g. DoD expansion)
  • J.POD® Redmond, WA, (US) opened in H2 2021
  • J.POD® Toulouse, France (EU) initiated in 2021 and start construction in 2022

J.POD® – commercial biologics manufacturing stepping up

EVOaccess – Progress and status

Significant expansion of alliances is basis for long-term success

Attraction, Extension, Retention

Customer base more diversified; revenues have grown significantly

• Integrated drug discover & development offering yields increasing "share of wallet"
• Faster and better results versus in-house infrastructures

• Solid customer retention rates
• Strong basis for double-digit growth

Healthy demand points to continued strong growth

Orders versus Revenues – Evotec SE and subsidiaries

• Healthy demand leads to strongest order book in company's history
• Near-shoring and post-pandemic market shake-up result in favourable environment
• Growth perspectives to result in bold investment decisions and capacity expansion as well as structural adjustments to accelerated growth

Despite P2x3 set back - The iceberg keeps growing

In total >220 projects: ~180 in partnerships, >40 internal R&D projects

				Neuroscience & Pain				Oncology			Inflammation & Metabolic Diseases Immunology1)				Virology		Anti-bacterial		Global Health
	Ph3	Jingxin																				SK bioscience
	Ph2	P2X3 - CC	P2X3 - OAB	P2X3 - DNP	Bayer – B1		BI/Xynomic			Carrick					P2X3
Clinical			Centrexion				Exscientia			Carrick					Bayer
	Ph1	Bayer	Bayer	BMS	Exscientia		Kazia			Carrick					Conba	Bayer	Topas					ND
					Aeovian					Exscientia			EVT		ND	Fibrocor	Topas	Sanofi
Preclinical		Bayer P2X3 FU Bayer			Exscientia					Exscientia	Carrick	Bayer	QRbeta		Topas	Topas	Exscientia	ND		Nosopharm	Forge
		ND	ND		Facio		Sanofi/ Apeiron	ND		Autobahn				Eternygen		Exscientia	LAB150
		ND	ND		Argobio		ND	ND	EVT	Immunitas				NephThera		Topas	LAB282					ND
		Bayer NDND	EVT	EVT	LAB282		ND	ND	EVT	Exscientia	Breakpoint	ND		LAB282		Celmatix	Fibrocor			ND	Forge	ND
		ND					EVT			Autobahn	DarkBlue	QRbeta	EVT		ND	ND	Celmatix
		ND					EVT			Breakpoint	LAB282	ND	EVT	NephThera	ND	ND	Blacksmith					ND
			ND	EVT	LAB282		EVT	EVT	Carrick	Blacksmith	Danube Labs	EVT	EVT	EVT	ND	Autobahn	Fibrocor		LAB282	Myxob	Forge	ND
Discovery							ND	EVT/MF				ND	ND					ND
		ND			Autobahn		ND	EVT/MF	EVT	Immunitas		ND	ND	EVT		Celmatix		ND
		ND	ND		Cajal Neuro		ND	EVT/MF	EVT	Quantro	BELAB1407	ND	ND 	EVT		CureXsys		ND
		ND	ND	EVT	Facio		ND	EVT/Indiv	EVT	Ananke	BELAB2122	ND	EVT	EVT		Exscientia		ND		ND		ND
		ND	ND	EVT	Exscientia		ND	EVT	EVT	Autobahn	LAB282	ND	EVT	LAB282	ND	Fibrocor		ND	ND	ND		ND
		ND	ND	EVT	CureXsys	LAB282	ND	EVT	EVT	Exscientia	LAB150	ND	EVT	LAB150	ND	LAB150		ND	Exscientia	ND	Forge	ND
		ND	ND	EVT	EVT	LAB150	ND	ND	EVT	OxVax	Argobio	ND	EVT N=4	NephThera	EVT	LAB282		ND	LAB282	ND	Exscientia	ND
	Positive clinical trial results € Key milestone achieved Development progress and/or new project Initiation of Partnered Pipeline Unpartnered Pipeline Equity Pipeline Bridges Pipeline New partnership clinical trial Phase change

1) Also includes Women's Health, Respiratory projects

The Equity Pipeline does not contain programs from EVT/partners that are not publically disclosed

"Evotec Inside"

Steady stream of high-value catalysts

Discovery

Selected pipeline events within next 12 – 24 months

• Phase III & registration (CHN) JingXin in insomnia (EVT201)
• Phase II data with Bayer in DNP (BAY2395840)
• Phase II initiation with Bayer in Gynaecology (BAY2395840)
• Phase I data in Chikungunya virus (EVT894)
• Phase I data with BMS in CNS (EVT8683)
• Phase I data with Exscientia in Oncology (EXS21546)
• Phase I data with Kazia in Oncology (EVT801)
• Phase I initiation in Covid-19 / HBV (EVT075)
• Phase I Initiation with Bayer in Kidney diseases
• Phase I Initiation with Kidney diseases with other partners
• Phase I initiation with BMS in CNS
• Phase I Initiation with BMS in Oncology
• Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

	Molecule	Therapeutic Area/Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III
	EVT201	Insomnia (GABA-A)
	Not Disclosed	Infectious Disease (Antibody)
	BAY2395840	Diabetic Neuropathic Pain (B1)
	CT7001	Oncology (CDK7)
	XP-105	Oncology (mTORC1/2)
	EVT401	Immunology & Inflammation (P2X7)
	BAY2328065	Gynaecology
	EXS21546	Oncology (various programmes)
Clinical	CNTX 6016	Pain (CB2)
	EVT894	Chikungunya (Antibody)
	Not Disclosed	Neuroscience & Pain	n.a.
	Not Disclosed	Neuroscience & Pain	n.a.
	EVT801	Oncology (VEGFR3)
	EVT8683	Neurodegeneration (eIF2b activator)
	TPM203	Pemphigus Vulgaris (ND)
	CT7001	Oncology (CDK7)
	CT7001	Oncology (CDK7)
	APN411	Oncology – Immunotherapy
	GLPGxxxx	Fibrosis (not disclosed)
	BAYxxxx	Nephrology (not disclosed)
	QRB001	Metabolic Diabetes (not disclosed) –
Pre-clinical	EVT075	Covid-19 / HBV	n.a.
	Not disclosed	Various programmes
	EVTxxxx	CNS, Metabolic, Pain, …	>10 further programmes

Multiple programmes across nephrology, oncology, immunology among other therapeutic areas

Precision medicine is the only path to improved medicine

Leading AI/ML driven drug discovery & development platforms

Deep understanding of biology for precision medicine

The Evotec Molecular Patient Database (E.MPD)

E.MPD core component of alliances in CKD

Example: CKD strategic drug discovery deals

	*
2016/17	2018/19	2020	2021	2022
 Upfront  Research funding  Milestones > € 300 m per product  Tiered royalties	 Vifor funded: € 25 m  50% on all projects  JV: NepThera	 Upfront  Research funding  Milestones > € 150 m per product  Tiered royalties	 Upfront  Research funding  Milestones  Tiered royalties	 Upfront  Research funding  Milestones US\$ 180 m per product  Tiered royalties

From Target identification & validation, via biomarker identification, to patient stratification

Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022

EVOequity accelerates co-owning strategy

Operational VC model – diversified portfolio with multiple shots on goal

Keeping the promise

ESG & Sustainability – Measures taken in 2021

Responsible use of resources

• Sourcing of 100% renewable energy since January 2021 at all German sites
• Decision to replace heating system in building B95 in Abingdon (est. CO2e savings of ~800t /yr)
• EVOearth week to raise overall awareness towards the protection of environment
• Software1) implementation for systematic emission data collection as basis to set SBTi targets

ESG topics part of our DNA

• Group-wide inclusion of ESG topics in personal 2021 targets of all employees
• Definition of responsibilities for delivering expanded set of sustainability KPIs
• Group-wide appreciation & celebration of diversity weeks in May and pride month in June
• DEI Diversity, Equity & Inclusion: Conception of global diversity strategy

Intensified stakeholder dialogue

• MSCI ESG rating up from BBB to A as of January 2021
• ISS ESG rating up from C- to C as of May 2021
• EcoVadis rank up from 48 pts to 53 pts in Q4
• Decision to report in reference to GRI standards for FY 2021 as SASB and TCFD are too "E"-focused

Strong news flow to be continued …

Selected latest news in Q1 2022

#RESEARCHNEVERSTOPS NEWS RELEASE, 21 MARCH 2022	evotec #RESEARCHNEVERSTOPS LEASE, 18 JANUARY 2022	evotec #RESEARCHNEVERSTOPS	evotec #RESEARCHNEVERSTOPS
EVOTEC RECEIVES € 3 M MILESTONE PAYMENT FOR BAYER STARTING PHASE II CLINICAL DEVELOPMENT OF DNP PROGRAMME > FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC > PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR DIABETIC NEUROPATHIC PAIN Hamburg, Germany, 21 March 2022: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain ("DNP"). DNP is a common chronic condition associated with nerve damage caused by high	EVOTEC AND LILLY ENTER INTO DRUG DISCOVERY COLLABORATION IN METABOLIC DISEASES > COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA- DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS > LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES Hamburg, Germany, 18 January 2022: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company ("Lilly") in the field of metabolic diseases with a focus on kidney diseases and diabetes.	LEASE, 25 JANUARY 2022 EVOTEC ENTERS IPSC-BASED DRUG DISCOVERY PARTNERSHIP WITH BOEHRINGER INGELHEIM IN OPHTHALMOLOGY ▶ PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS > AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS Hamburg, Germany, 25 January 2022: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent	LEASE, 11 JANUARY 2022 EVOTEC EXPANDS NEUROSCIENCE COLLABORATION WITH BRISTOL MYERS SQUIBB TO INCLUDE NEW TARGETED PROTEIN DEGRADATION APPROACH > EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS > EVOTEC RECEIVES PAYMENTS OF IN TOTAL US\$ 15 M FROM BRISTOL MYERS SOUIBB	evotec #RESEARCHNEVERSTOPS LEASE, 03 JANUARY 2022 EVOTEC REGEIVES € 7.5 M GRANT FOR DEVELOPMENT OF COVID-19 THERAPEUTIC · EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19 > EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF DIFFICULT DISEASE PROGRESSION AND HOSPITALISATION Hamburg, Germany, 03 January 2022:
blood sugar levels in diabetic patients. DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain. Thus, DNP can drastically impair the quality of life for people living with this condition. BAY 2395840 is an investigational oral antagonist of the bradykinin receptor B1 ("BDKRB1"), which is known to play a role in pain perception. Bayer has initiated a Phase II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo. The phase II study is anticipated to run until the end of 2022. Dr Cord Dohrmann. Chief Scientific Officer of Evotec, commented: "We are excited that Bayer is moving ahead with the Phase II clinical development of an asset from our multi-target research alliance. The role of the bradykinin receptor Br for pain reception is well documented. We are confident that the highly selective BDKRB1 antagonist BAY 2395840 stands a good chance to provide a new, urgently needed therapeutic option for DNP patients."	The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation. The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US\$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US\$ 1 bn. Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to enter into this research partnership with Lilly. Over a period of several years, Evotec has systematically built a proprietary patient database by conducting multi-omics analyses of biospecimens from patient biobanks covering metabolic and kidney diseases. Evotec's patient-derived molecular data in combination with our	stem cell ("iPSC")-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions. Through phenotypic screening of human iPSC-derived cells, supported by Evotec's PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions. Boehringer Ingelheim will then continue with the discovery and development of potential therapeutic candidates. Besides an undisclosed upfront and FTE-based research payment, Evotec will continue to benefit from the successful further development of the candidates in the form of milestones and layered royalties. Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to utilise our unique iPSC- and PanOmics-based approaches to ophthalmologic diseases in this new partnership with Boehringer Ingelheim. Phenotypic screening approaches have a long history of delivering highly effective drugs based on novel molecular mechanisms. Phenotypic screens based on human iPSC-derived disease models combined with our unbiased PanOmics readouts are more likely to deliver disease relevant drugs than any other cell-based screening approach."	Hamburg, Germany, 11 January 2022: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb (NYSE:BMY) with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer's through a novel approach to targeted protein degradation. Evotec receives payments totalling US\$ 15 m from Bristol Myers Squibb. Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions. Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Our collaboration with Bristol Myers Squibb in the field of neurodegenerative disease continues to be highly productive. Many neurodegenerative diseases are driven by disease-causing proteins which have proven to be elusive to traditional drug discovery approaches. We are committed to continuously explore novel drug targeting mechanisms and modalities and are delighted to have a strong partner with BMS in this endeavour. The neurodegeneration collaboration between Evotec and Bristol Myers Squibb was	Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has been selected by the German Federal Ministry of Education and Research ("BMBF") to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19. Under the C 7.5 m grant, Evotec will use clinical manufactured within its Just - Evotec Biologics manufacturing platform to initiate the clinical development of a potentially highly potent immunomodulatory molecule. Utilising the assays developed as part of the Company's global Pandemic Preparedness and Rapid Response initiative "PRROTECT", Evotec has demonstrated potent activity of the molecule in pre-clinical in-vitro studies. The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2 ("coronavirus"). By amplifying the immune response against coronavirus infections, the molecule can potentially reduce the viral load. Thus, the early administration of this biologic may significantly lower the risk of a severe progression of COVID-19 that requires hospitalisation of patients.
			initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients' symptoms despite a huge unmet medical	Evotec intends to use the grant to initiate clinical studies assessing the safety and efficacy of the compound and to determine the optimal dose-range in healthy volunteers as well as COVID-19 patients. Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "As we enter the third year of the COVID-19 pandemic, it has become apparent that

Setting the pace to accelerate growth along Action Plan 2025

Selected key events to watch 2022

	R&D efficiency platforms	 Undisrupted growth in line with AP 2025; Continued double digit growth of base business (EVOiR&D)  Significant capacity and value chain expansion for all modalities and sites
	Precision medicine platforms	 New strategic partnerships, important milestones, and expansions of co owned alliances; Multiple clinical trial initiations and progression of co owned pipeline; (EVOroyalty)  Spin-Offs and investments along Building Blocks of AP 2025 (EVOequity)
	Just – Evotec Biologics	 Start of production J.POD® Redmond, WA (US); Start of construction J.POD® Toulouse, France (EU)  Multiple new partnerships (EVOaccess)

Our mid-term aspirations are "… just the beginning"

2020-2025e Key Performance Indicator goals

Upcoming important dates

Financial calendar 2022

Quarterly Statement Q1 2022	11 May 2022
Virtual Annual General Meeting 2022	22 June 2022
Half-year 2022 Interim Report	11 August 2022
Quarterly Statement 9M 2022	09 November 2022	Full annual report and sustainability report 2021 available for download on 26 April 2022

PAGE 40

Appendix

Profit & Loss Statement

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

in k€ except share and per share data	Year ended 31 December 2021	Year ended 31 December 2020
Revenues	618 034	500 924
Costs of revenue	(466 491)	(375 181)
Gross profit	151 543	125 743
Operating income and (expenses)
Research and development expenses	(72 200)	(63 945)
Selling, general and administrative expenses	(105 445)	(77 205)
Impairment of intangible assets	(683)	(3 244)
Impairment of goodwill	–	–
Other operating income	73 472	72 175
Other operating expenses	(5 691)	(4 968)
Total operating income and (expenses)	(110 547)	(77 187)
Operating income	40 996	48 556
Total non-operating income (expense)	195 984	(22 716)
Total taxes	(21 470)	(19 562)
Net income	215 510	6 278
thereof attributable to:
Shareholders of Evotec SE	215 510	6 278
Non-controlling interest	–	–
Weighted average shares outstanding	166 405 926	153 752 241
Net income per share (basic)	1,30	0,04
Net income per share (diluted)	1,30	0,04

Balance Sheet

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

in k€	as of 31 December 2021	as of 31 December 2020
ASSETS
Current assets
Cash and cash equivalents	699 326	422 580
Investments	158 908	59 350
Trade accounts receivables	132 078	79 005
Prepaid expenses and other current assets	39 895	30 404
Other	70 733	67 505
Total current assets	1 100 940	658 844
Non-current assets
Long-term investments	268 793	19 289
Long-term investments accounted for using the equity method	13 068	39 710
Property, plant and equipment	484 597	337 297
Intangible assets, excluding goodwill	30 851	98 036
Goodwill	257 569	247 370
Other	79 343	61 791
Total non-current assets Total assets	1 134 221 2 235 161	803 493 1 462 337
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Current loan liabilities	36 136	15 392
Current portion of lease obligations Trade accounts payable	14 473 72 598	14 616 42 549
Provisions	39 260	41 848
Contract liabilities	112 061	66 477
Other	49 988	27 577
Total current liabilities	324 516	208 459
Non-current liabilities:
Non-current loan liabilities	326 344	331 019
Long-term lease obligations	135 964	130 938
Contract liabilities	33 476	22 437
Other	37 176	45 028
Total non-current liabilities	532 960	529 422
Equity attributable to shareholders of Evotec SE	1 377 685	724 456
Non-controlling interest	-	-
Total stockholders' equity	1 377 685	724 456
Total liabilities and stockholders' equity	2 235 161	1 462 337

Cash Flow Statement

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

in k€	2021	2020
Cash flows from operating activities
Net income	215 510	6 278
Depreciation of property, plant and equipment	55 596	42 122
Amortisation of intangible assets	12 012	13 936
Depreciation of current assets	2 791	160
Impairment of intangible assets	683	3 244
Fair value adjustments on long-term investments	(223 791)	(1 500)
Accounts receivables	(48 032)	(4 178)
Inventories	(11 653)	(3 631)
Accounts payable	31 341	2 165
Contract liabilities and deferred income	63 083	(14 618)
Other	24 697	743
Net cash provided by operating activities	122 237	44 721
Cash flows from investing activities
Purchase of current investments	(123 696)	(70 932)
Purchase of property, plant and equipment	(118 943)	(99 072)
Other	(1 216)	14 915
Net cash used in investing activities	(243 855)	(155 089)
Net cash provided by (used in) financing activities	398 430	246 409
Net increase (decrease) in cash and cash equivalents	276 812	136 041
Exchange rate difference	(66)	9 505
Cash and cash equivalents at beginning of year	422 580	277 034
Cash and cash equivalents at end of the period	699 326	422 580
Supplemental schedule of non-cash activities
Additions to leases	14 292	68 044

Your contact:

Volker Braun SVP Head of Global Investor Relations & ESG

+49.(0).40.560 81-775 +49.(0).151.1950 4058 volker.braun@evotec.com